Enthusiasm wanes as AstraZeneca’s zibotentan nears endothelin-A graveyard
This article was originally published in Scrip
Executive Summary
AstraZeneca's disappointing late-stage oncology programme continues its run of bad luck with the failure of another Phase III trial of zibotentan in prostate cancer, raising the question of whether any endothelin-A receptor antagonists will succeed in this indication.